Literature DB >> 16173829

Whole-body PET/MRI: the future in oncological imaging.

Marcus D Seemann1.   

Abstract

Positron emission tomography (PET) facilitates the evaluation of molecular aspects and metabolic alterations that are fundamental in detecting of malignancies, characterization of tumor stage and assessment of therapeutical response, and tumor recurrence. The main advantage of PET is its high sensitivity in identifying of areas of cancerous involvement at an early stage. In general, the accelerated radiotracer activity occurs before anatomical structure changes. The main difficulty with PET is the lack of an anatomical reference frame. Magnetic resonance imaging (MRI) is an excellent morphological imaging modality with a high anatomical resolution. Whole-body MRI produce large amounts of image data, resulting in the possibility of overlooking subtle pathological findings. The fusion of PET with MRI can compensate for their disadvantages and therefore offers several advantages in comparison to PET or MRI alone. The combination of these two excellent diagnostic imaging modalities into a single scanner improves the diagnostic accuracy by facilitating the accurate registration of molecular aspects and metabolic alterations of the diseases with exact correlation to anatomical findings and morphological information. Whole-body PET/MRI is a very promising diagnostic modality for oncological imaging and for use in cancer screening in the decades to come due to the considerably lower radiation exposure in contrast to PET/CT and the high soft tissue resolution of MRI.

Entities:  

Mesh:

Year:  2005        PMID: 16173829     DOI: 10.1177/153303460500400512

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  19 in total

1.  Protein Nanospheres: Synergistic Nanoplatform-Based Probes for Multimodality Imaging.

Authors:  Michael A McDonald; Paul C Wang; Eliot L Siegel
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2011-01-24

2.  Navigating beyond the 6th dimension: a challenge in the era of multi-parametric molecular imaging.

Authors:  Habib Zaidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-07       Impact factor: 9.236

Review 3.  Resolution modeling in PET imaging: theory, practice, benefits, and pitfalls.

Authors:  Arman Rahmim; Jinyi Qi; Vesna Sossi
Journal:  Med Phys       Date:  2013-06       Impact factor: 4.071

Review 4.  Dynamic whole-body PET imaging: principles, potentials and applications.

Authors:  Arman Rahmim; Martin A Lodge; Nicolas A Karakatsanis; Vladimir Y Panin; Yun Zhou; Alan McMillan; Steve Cho; Habib Zaidi; Michael E Casey; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-29       Impact factor: 9.236

5.  CXCR-4 Targeted, Short Wave Infrared (SWIR) Emitting Nanoprobes for Enhanced Deep Tissue Imaging and Micrometastatic Cancer Lesion Detection.

Authors:  Margot Zevon; Vidya Ganapathy; Harini Kantamneni; Marco Mingozzi; Paul Kim; Derek Adler; Yang Sheng; Mei Chee Tan; Mark Pierce; Richard E Riman; Charles M Roth; Prabhas V Moghe
Journal:  Small       Date:  2015-10-30       Impact factor: 13.281

6.  Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer.

Authors:  Matthias Eiber; Isabel Rauscher; Michael Souvatzoglou; Tobias Maurer; Markus Schwaiger; Konstantin Holzapfel; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-12       Impact factor: 9.236

7.  In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent.

Authors:  Charles Glaus; Raffaella Rossin; Michael J Welch; Gang Bao
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

8.  Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions.

Authors:  Matthias Eiber; Axel Martinez-Möller; Michael Souvatzoglou; Konstantin Holzapfel; Anja Pickhard; Dennys Löffelbein; Ivan Santi; Ernst J Rummeny; Sibylle Ziegler; Markus Schwaiger; Stephan G Nekolla; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-18       Impact factor: 9.236

Review 9.  Molecular imaging of in vivo gene expression.

Authors:  Allison S Harney; Thomas J Meade
Journal:  Future Med Chem       Date:  2010-03       Impact factor: 3.808

Review 10.  Multimodality imaging: beyond PET/CT and SPECT/CT.

Authors:  Simon R Cherry
Journal:  Semin Nucl Med       Date:  2009-09       Impact factor: 4.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.